Free account + included starter software — credential review typically takes 1–2 business days. See how it works
NDC 50228-0460-01

Carbidopa and Levodopa 25 mg/1, 100 mg/1 TABLET, EXTENDED RELEASE

ScieGen Pharmaceuticals Inc

In Stock at Premier Pharma
NDC
50228-0460-01
Generic Name
Carbidopa and Levodopa
Brand Name
Carbidopa and Levodopa
Strength
25 mg/1, 100 mg/1
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Package Size
Labeler
ScieGen Pharmaceuticals Inc

FDA Drug Information

Indications & Usage

INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets, USP are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Important Warnings

WARNINGS When patients are receiving levodopa without a decarboxylase inhibitor, levodopa must be discontinued at least twelve hours before carbidopa and levodopa extended-release tablets are started. In order to reduce adverse reactions, it is necessary to individualize therapy. See DOSAGE AND ADMINISTRATION section before initiating therapy. Carbidopa and levodopa extended-release tablets should…

Source: FDA. For professional use only. Not a substitute for prescribing information.

Order NDC 50228-0460-01 at Wholesale

Create a free Premier Pharma account to unlock live wholesale pricing and place orders with same-day fulfillment and full DSCSA T2 documentation (TI + TS).